Cargando…

Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study

BACKGROUND: Denosumab inhibits the receptor activator of nuclear factor κB (RANK) pathway and is used to treat osteoporosis. Emerging evidence suggests RANK-blockade may play a role in mammary tumourigenesis. Thus, we undertook a population-based study of denosumab use and breast cancer risk in a la...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannakeas, Vasily, Cadarette, Suzanne M., Ban, Joann K., Lipscombe, Lorraine, Narod, Steven A., Kotsopoulos, Joanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265331/ https://www.ncbi.nlm.nih.gov/pubmed/30420611 http://dx.doi.org/10.1038/s41416-018-0225-4

Ejemplares similares

Salpingectomy and the Risk of Ovarian Cancer in Ontario
por: Giannakeas, Vasily, et al.
Publicado: (2023)

Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period
por: Giannakeas, Vasily, et al.
Publicado: (2022)

Platelet Count and Survival after Cancer
por: Giannakeas, Vasily, et al.
Publicado: (2022)

Survival Differences in Chinese Versus White Women With Breast Cancer in the United States: A SEER-Based Analysis
por: Lim, David W., et al.
Publicado: (2020)

A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy
por: Giannakeas, Vasily, et al.
Publicado: (2019)

A Validation of Methods for the Evaluation of Observational Studies of Screening Mammography: An Exploratory Analysis Based on Simulating Screening Cohorts
por: Giannakeas, Vasily, et al.
Publicado: (2020)

Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy
por: Giannakeas, Vasily, et al.
Publicado: (2018)

Time to death in breast cancer patients as an indicator of treatment response
por: Narod, Steven A., et al.
Publicado: (2018)

Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer
por: Giannakeas, Vasily, et al.
Publicado: (2020)

Survival of Filipino women with breast cancer in the United States
por: Lim, David W., et al.
Publicado: (2023)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis
por: Pitale, Shailesh, et al.
Publicado: (2015)

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Zaman, Tasnim, et al.
Publicado: (2019)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Emerging applications of tumour-educated platelets in the detection and prognostication of ovarian cancer
por: Zhu, Jiewei, et al.
Publicado: (2023)

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
por: Silverman, Stuart L., et al.
Publicado: (2018)

Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
por: Lai, E. C.-C., et al.
Publicado: (2022)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2016)

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS
por: Mirzaei, Alireza, et al.
Publicado: (2021)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study
por: Rossini, Alessandro, et al.
Publicado: (2020)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
por: Słopień, Radosław, et al.
Publicado: (2017)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension
por: Koh, Jung-Min, et al.
Publicado: (2016)

Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation
por: Guyonnet, Emma, et al.
Publicado: (2023)

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
por: Bone, Henry G., et al.
Publicado: (2013)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j6f1v1nkod2hneknbn778vh5ho